1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Flerie AB

Flerie AB

15.20
SEK
0.00
(0.00%)
1.75BMarket Cap
Jan 20Next Earn
Flerie AB
STO:FLERIE
(Nasdaq Stockholm)

Recent

price

15.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
24.77
0.21
0.06
0.02
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-8.16
-16.39
-13.33
-14.3
-15.87
-14.62
-7.96
-18.65
-16.48
-9.92
-2.83
-9.4
- -
Basic EPS, GAAP
-4.51
-20.27
-10.31
-13.24
-15.18
-14.17
-9.92
-22.46
-21.26
-1.31
-0.21
-0.35
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
12.44
0.23
35.79
21.48
11.54
14.76
6.84
71.3
54.86
585.72
47.05
38.15
39.14
Book Value per Share
12.44
0.23
35.15
21.03
11.29
14.7
6.84
71.3
54.86
585.72
47.05
38.15
39.14
Tangible Book Value per Share
2
2
3
5
5
6
7
6
6
56
81
81
90
Basic Weighted Avg Shares
45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-26.98
-7,838.83
-22,471.02
-64,801.77
-64,060.94
-99,672.73
-163,854.29
- -
- -
- -
-105,600
- -
- -
Operating Margin (%)
- -
- -
- -
1
1
1
1
1
1
1
1
1
- -
Depreciation Expense
-15
-30
-41
-73
-82
-88
-57
-103
-100
-560
-228
-757
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-32.93
-7,947.07
-23,451.7
-64,312.39
-64,178.12
-99,742.05
-164,051.43
- -
- -
- -
-228,000
- -
- -
Profit Margin (%)
30
- -
181
108
64
106
47
432
333
436
1,006
713
550
Working Capital
- -
- -
2
1
- -
- -
2
- -
3
1
- -
2
1
LT Debt
30
1
182
109
64
107
49
434
334
3,566
4,198
3,377
3,394
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-193.09
-45.27
-49.95
-94.61
-102.66
-73.69
-42.64
-26.13
-28.7
-5.87
-19.98
- -
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
89
95
87
Market Capitalization
2,901
3,029
1,751

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
727
783
558
Cash, Cash Equivalents & STI
540
585
306
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
- -
Total Current Liabilities
14
8
8
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3,460.86%
344.55%
-19.56%
Free Cash Flow
12.94%
4.61%
65.29%
Net Income, GAAP
80.68%
141.46%
231.97%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
1
- -
2025
- -
9
- -
1
- -
2026
- -
1
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-24.56
1.39
-1.31
-0.72
-2.83
2025
-2.81
2.22
- -
-6.11
-9.4
2026
-0.68
-1.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Flerie AB (publ) is a dynamic life science investment firm, having listed publicly on Nasdaq Stockholm in mid-2024. It focuses on early-stage and growth opportunities within the biotechnology and pharmaceutical industries. The firm strategically invests in companies dedicated to advancing novel drug therapies and associated technological platforms that address significant medical needs globally. Flerie is committed to an active ownership model, providing resources and support across its diversified portfolio, primarily composed of around 30 innovative enterprises. Its investment reach spans Europe, the United States, and Israel. Established in 2011, the company maintains its primary operations in Stockholm, Sweden, complemented by an office in London, United Kingdom. A substantial capital raise completed in 2024 has further strengthened its capacity for strategic portfolio expansion and development.